Key Highlights

  • Faron Pharmaceuticals Oy (LSE:FARN) gained 9.51% on 28 September 2026, placing the clinical-stage biotechnology company among the strongest movers.
  • Investor attention remains concentrated on bexmarilimab, Faron's wholly owned investigational anti-Clever-1 immunotherapy.
  • The company has reported encouraging survival observations from the BEXMAB Phase 1/2 programme in higher-risk myelodysplastic syndromes.
  • Faron is preparing for the next stage of development through the planned randomized Phase 2b BEXERA trial in frontline higher-risk MDS.
  • The company recently announced its R&D Day for 8 October 2026, creating a near-term potential catalyst for additional clinical and development information.
  • Faron completed a €40.1 million rights issue in April 2026, strengthening funding for its clinical development programme.
  • Cash and cash equivalents stood at approximately €32.0 million at 30 June 2026, compared with €13.5 million a year earlier.
  • Investors are watching clinical data, trial progression, financing requirements, regulatory milestones and the potential commercial opportunity for bexmarilimab.

Why Is Faron Pharmaceuticals (LSE:FARN) in Focus Today?

Faron Pharmaceuticals has attracted renewed attention after LSE:FARN gained 9.51% on 28 September 2026.

The company is a clinical-stage biotechnology Business developing novel immunotherapies, with its lead asset, bexmarilimab, representing the central focus of its Investment story.

Unlike a conventional pharmaceutical company with marketed products and recurring commercial revenue, Faron's valuation is strongly influenced by clinical development milestones.

That makes clinical data, trial design, patient recruitment, regulatory progress and financing particularly important.

The latest move comes as several potential catalysts are approaching, most notably Faron's planned R&D Day on 8 October 2026.

Why Is Bexmarilimab So Important for LSE:FARN?

Bexmarilimab is an investigational immunotherapy designed to target Clever-1, an immunosuppressive receptor associated with macrophage activity within the tumour environment.

Faron's development strategy is based on the idea that modifying this immune environment could help restore anti-tumour immune activity and improve responses to existing cancer treatments.

The company is developing bexmarilimab across multiple cancer indications.

Higher-risk myelodysplastic syndromes currently represent one of the most important development areas.

The potential significance of the programme is that Faron is attempting to develop a treatment that could be used alongside existing standards of care rather than functioning exclusively as a standalone therapy.

What Has Faron Reported From the BEXMAB Programme?

Recent BEXMAB data have been an important source of investor interest.

The Phase 1/2 study is evaluating bexmarilimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes.

An updated overall-survival analysis reported in July 2026 showed that median overall survival had not yet been reached in treatment-naïve higher-risk MDS patients without TP53 mutations and in the monoallelic TP53 subgroup at the time of the analysis.

The biallelic TP53 subgroup had a median overall survival of 8.8 months, broadly in line with historical outcomes for this particularly aggressive disease subgroup.

Importantly, survival follow-up remains ongoing, meaning the dataset can continue to mature.

For investors, the key issue is not simply the current median figures but whether future follow-up produces increasingly durable clinical evidence.

Why Is BEXERA a Major Catalyst?

The next major stage in Faron's development strategy is the planned BEXERA randomized Phase 2b trial.

The programme is focused on frontline higher-risk MDS and represents a significant transition from earlier-stage clinical investigation towards a more definitive evaluation of bexmarilimab.

The €40.1 million rights issue completed in April was specifically important because management identified the BEXERA programme as a major use of the newly raised capital.

Successful execution of BEXERA could therefore become one of the most important value-driving milestones for LSE:FARN.

Investors will be watching trial design, regulatory progress, patient recruitment, treatment combinations and eventual efficacy results.

Why Is the 8 October R&D Day Important?

Faron has scheduled an R&D Day for 8 October 2026.

The timing is significant because it provides investors with an opportunity to receive additional information about the company's Research and Development strategy.

Attention is likely to centre on:

  • Bexmarilimab development priorities
  • BEXERA trial planning
  • BEXMAB clinical data
  • Solid-tumour programmes
  • Investigator-initiated trials
  • Development timelines
  • Potential future clinical milestones

For a clinical-stage biotech, investor events focused on research and development can become important catalysts because small changes in clinical expectations can materially affect market sentiment.

What Is Happening Beyond MDS?

Faron is also expanding the clinical development of bexmarilimab into solid tumours.

The company's investigator-initiated trial portfolio includes multiple studies evaluating combinations with established cancer treatments.

One programme, BLAZE, is being developed with an anti-PD-1 therapy and has received regulatory and ethical approvals to advance towards patient enrolment.

Faron has also reported progress in other investigator-led studies.

This broadens the potential application of bexmarilimab beyond MDS, although each programme remains subject to clinical and regulatory uncertainty.

Why Is Faron's Cash Position Important?

Funding is a critical consideration for LSE:FARN because the company does not yet have commercial product Revenue capable of supporting its research and development activities.

Faron reported approximately €32.0 million of cash and cash equivalents at 30 June 2026, compared with €13.5 million at the end of June 2025.

The major reason for the stronger financial position was the €40.1 million rights issue completed in April 2026.

The financing provides a significantly stronger foundation for the company's next stage of clinical development.

However, continued research and clinical-trial expenditure means investors will continue monitoring cash consumption and future financing requirements.

What Could Explain the 9.51% Rise on 28 September 2026?

The 9.51% gain comes against a backdrop of increasing attention around Faron's clinical pipeline.

The most identifiable factors include the company's encouraging BEXMAB survival update, preparations for BEXERA, the expanding investigator-initiated trial portfolio and the upcoming R&D Day.

The recent financing also gives the company greater visibility over the funding of its near-term development programme.

The exact contribution of each Factor to the day's share-price movement cannot be isolated.

However, the concentration of upcoming clinical and corporate milestones provides important context for the renewed activity in LSE:FARN.

What Are the Main Risks for Faron Pharmaceuticals?

Clinical-stage biotechnology companies carry substantial development risk.

Positive early-stage or interim data do not guarantee success in later-stage trials.

BEXERA will therefore be an important test of whether earlier observations can be reproduced in a larger, randomized setting.

Other risks include trial delays, patient recruitment challenges, regulatory requirements, financing needs and potential competition from alternative treatments.

Faron also remains dependent on successful development of bexmarilimab because the company currently has no established commercial product generating significant recurring revenue.

What Should Investors Watch Next for LSE:FARN?

Key areas include:

  • 8 October 2026 R&D Day
  • BEXERA trial preparations
  • BEXMAB survival follow-up
  • Higher-risk MDS clinical data
  • TP53 subgroup outcomes
  • Investigator-initiated trials
  • Solid-tumour development
  • Patient recruitment
  • Regulatory milestones
  • Cash consumption
  • Future funding requirements
  • Potential licensing or strategic partnerships

The Maturity of the clinical dataset will be particularly important as investors assess whether bexmarilimab can progress towards larger-scale clinical development.

Faron Pharmaceuticals (LSE:FARN) Outlook

Faron Pharmaceuticals' 9.51% share-price gain on 28 September 2026 places renewed attention on one of the UK's listed clinical-stage biotechnology companies.

The central issue for LSE:FARN remains the development of bexmarilimab.

Recent BEXMAB data, the planned BEXERA Phase 2b programme, expansion into additional indications and the upcoming R&D Day have created a concentrated period of potential clinical catalysts.

The stronger cash position following the €40.1 million rights issue provides additional funding visibility, although ongoing clinical development will continue to require substantial resources.

For LSE:FARN, the next stage is likely to be defined by the quality and durability of clinical evidence, progress towards BEXERA and the company's ability to translate its scientific platform into later-stage clinical development.